Simeng Lu

Dr. Simeng Lu


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2024 in Cancers
Verified
Journal Article
Open access
PDF file
SLSimeng Lu
Simeng Lu
ZYZhenzhen Yin
Zhenzhen Yin
JCJie Chen
Jie Chen
LWLimeng Wu
Limeng Wu
YSYao Sun
Yao Sun
LXLei Xu
Lei Xu
NF2-related Schwannomatosis (NF2-SWN) is a disease that needs new solutions. The hallmark of NF2-SWN, a dominantly inherited neoplasia syndrome, is bilateral vestibular schwannomas (VSs), which progressively enlarge, leading to sensorineural hearing loss, tinnitus, facial weakness, and pain that translates to social impairment and clinical depression. Standard treatments for growing VSs include surgery and radiation therapy (RT); however, both carry the risk of further nerve damage that can result in deafness and facial palsy. The resultant suffering and debility, in combination with the paucity of therapeutic options, make the effective treatment of NF2-SWN a major unmet medical need. A better understanding of these mechanisms is essential to developing novel therapeutic targets to control tumor growth and improve patients’ quality of life. Previously, we developed the first orthotopic cerebellopontine angle mouse model of VSs, which faithfully mimics tumor-induced hearing loss. In this model, we observed that mice exhibit symptoms of ataxia and vestibular dysfunction. Therefore, we further developed a panel of five tests suitable for the mouse VS model and investigated how tumor growth and treatment affect gait, coordination, and motor function. Using this panel of ataxia tests, we demonstrated that both ataxia and motor function deteriorated concomitantly with tumor progression. We further demonstrated that (i) treatment with anti-VEGF resulted in tumor size reduction, mitigated ataxia, and improved rotarod performance; (ii) treatment with crizotinib stabilized tumor growth and led to improvements in both ataxia and rotarod performance; and (iii) treatment with losartan did not impact tumor growth nor ameliorate ataxia or motor function. Our studies demonstrated that these methods, paired with hearing tests, enable a comprehensive evaluation of tumor-induced neurological deficits and facilitate the assessment of the effectiveness of novel therapeutics to improve NF2 treatments.

11 January 2026 in Cancers
Verified
Journal Article
Open access
PDF file
BZBoshi Zhang
Boshi Zhang
SLSimeng Lu
Simeng Lu
Scott PlotkinScott Plotkin
Scott Plotkin
LXLei Xu
Lei Xu
NF2-related Schwannomatosis (NF2-SWN) remains a disorder with few effective treatment options. Patients develop vestibular schwannomas (VSs) on both auditory nerves, which gradually impair hearing and often result in significant communication difficulties, social withdrawal, and higher rates of depression. Progress in understanding NF2-SWN biology and translating discoveries into therapies has been slowed by the absence of robust animal models that faithfully reproduce both tumor behavior and the associated neurological deficits. In this review, we summarized the development of animal models that not only reproduce tumor growth in the peripheral nerve microenvironment but also reproduce tumor-induced neurological symptoms, such as hearing loss and ataxia. We further highlight the currently available organotypic models for NF2-SWN. Together, these systems provide an essential foundation for advancing mechanistic studies and accelerating the development of effective therapies for this devastating disorder.

21 February 2026
Verified
Dataset
Closed access
PDF file
SLSimeng Lu
Simeng Lu
DBDay Caven Blake
Day Caven Blake
AJAdam P. Jones
Adam P. Jones
LXLei Xu
Lei Xu
NF2-related schwannomatosis (NF2-SWN) is an autosomal dominant tumor predisposition syndrome caused by germline mutations in the NF2 tumor suppressor gene. The disease is characterized by the development of bilateral vestibular schwannomas (VSs), which progressively enlarge and result in hearing loss, imbalance, and ataxia-symptoms that profoundly affect patients' quality of life. No FDA-approved pharmacologic treatments are currently available. Among the neurological deficits, ataxia remains a particularly debilitating yet understudied manifestation, largely due to the lack of robust preclinical models for its evaluation. In this study, we developed a set of behavioral assays to systematically assess tumor-induced ataxia in an orthotopic mouse model of VS-associated hearing loss and ataxia. These tests allow quantitative measurement of balance and motor coordination deficits arising from tumor burden. This experimental platform enables mechanistic studies of tumor-induced cerebellar dysfunction and provides a valuable tool for preclinical evaluation of therapeutic strategies. By integrating behavioral assessments with tumor biology and hearing tests, this approach facilitates the characterization of both tumor-suppressive and neuroprotective treatment effects. Ultimately, these assays offer a versatile framework that can also be applied to other neurological disorders characterized by ataxia, expanding their utility beyond NF2-SWN.

20 February 2026 in Journal of Visualized Experiments
Verified
Journal Article
Closed access
PDF file
SLSimeng Lu
Simeng Lu
DBDay Caven Blake
Day Caven Blake
AJAdam P. Jones
Adam P. Jones
LXLei Xu
Lei Xu
NF2-related schwannomatosis (NF2-SWN) is an autosomal dominant tumor predisposition syndrome caused by germline mutations in the NF2 tumor suppressor gene. The disease is characterized by the development of bilateral vestibular schwannomas (VSs), which progressively enlarge and result in hearing loss, imbalance, and ataxia-symptoms that profoundly affect patients' quality of life. No FDA-approved pharmacologic treatments are currently available. Among the neurological deficits, ataxia remains a particularly debilitating yet understudied manifestation, largely due to the lack of robust preclinical models for its evaluation. In this study, we developed a set of behavioral assays to systematically assess tumor-induced ataxia in an orthotopic mouse model of VS-associated hearing loss and ataxia. These tests allow quantitative measurement of balance and motor coordination deficits arising from tumor burden. This experimental platform enables mechanistic studies of tumor-induced cerebellar dysfunction and provides a valuable tool for preclinical evaluation of therapeutic strategies. By integrating behavioral assessments with tumor biology and hearing tests, this approach facilitates the characterization of both tumor-suppressive and neuroprotective treatment effects. Ultimately, these assays offer a versatile framework that can also be applied to other neurological disorders characterized by ataxia, expanding their utility beyond NF2-SWN.